A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Afamitresgene autoleucel (Primary)
Indications Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Synovial sarcoma
Focus Adverse reactions
Acronyms SPEARHEAD-3 Pediatric Study
Sponsors Adaptimmune

15 Feb 2024 Status changed from not yet recruiting to recruiting.
19 Sep 2023 Planned initiation date changed from 30 Aug 2023 to 31 Oct 2023.
10 Aug 2023 Planned End Date changed from 30 Jun 2038 to 30 Jul 2038.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com